DeutschNewstral
Article
bizjournals.com on 2017-01-18 13:22
Eli Lilly will pay $960M for migraine-focused Cambridge biotech
Related news
- Eli Lilly joins biotech stampede into Cambridge with new innovation centerbizjournals.com
- Fast-growing Cambridge biotech Sigilon inks $63M diabetes deal with Eli Lillybizjournals.com
Eli Lilly ordered to pay $176.5 mln to Teva in US migraine drug patent trialThe Jerusalem Post (JPost.com)- MBiotech ETFs surge, supported by strong results from Biogen and Eli Lillymarketwatch.com
- Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotechbizjournals.com
- Pharma giant Eli Lilly acquires Cambridge startup Disarm Therapeuticsbizjournals.com
- LMigraine Drugs Market 2021 Latest Insights, Growth Rate, Future Trends and Forecast | Oprating Vendors: GlaxoSmithKline, Teva Pharma, Amgen, Allergan, Pfizer, Eli Lilly…liverpoolstudentmedia.com
Eli Lilly Exploring Elanco Spinoffwsj.com- Eli Lilly CEO to Retirewsj.com
- FEli Lilly and Immunocore to collaborateft.com
- FEli Lilly & Co: Eli Lilly predicts sales jump from obesity drug demandft.com
- MEli Lilly says FDA has approved new migraine drug Emgalitymarketwatch.com
Express Scripts targets Amgen, Lilly migraine drugs in pricing shiftwenatcheeworld.com
Eli Lilly & Co. v. Perrigo Co.jdsupra.com- FAstraZeneca and Eli Lilly scrap Alzheimer’s trialft.com
Obesity drug shows promise, Eli Lilly saysArkansas Online- MEli Lilly (LLY) earnings This fall 2023mvtelegraph.com
Eli Lilly to offer half-price insulinnwaonline.com- MEli Lilly hikes dividend by 8%marketwatch.com
Eli Lilly, Urban Outfitters skid; Deere climbsThe Salt Lake Tribune